ArticlesThe presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study
Introduction
Chronic obstructive pulmonary disease (COPD) is characterised by poorly reversible airflow limitation that usually worsens with time1 and is thought to be related to an enhanced inflammatory response to inhaled particles and gases.2 Quantitative pathological studies of the lung have shown that airflow limitation can be caused by a loss of lung elastic recoil due to emphysematous destruction of the lung parenchyma,3 by destruction or remodelling of the small airways,4, 5 or by some combination of these processes.
Emphysema can be quantified by CT scanning,6, 7 since low density areas in the lungs have been shown to correlate with the degree of lung function impairment8, 9, 10 and can be used to predict an accelerated decline in forced expiratory volume in 1 s (FEV1).1, 10, 11 Thus, serial CT scanning has been proposed as a potential method to monitor the progression of emphysema.12 In fact, trials of α1-antitrypsin augmentation therapy have used change in CT lung density as an outcome measure.13, 14 However, in COPD, the prevalence of emphysema and its relation to FEV1 varies substantially between patients.15, 16 There are currently little data about the change in CT lung density and the role of potential biomarkers in predicting emphysema progression in COPD.10
We used data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study,17 a large observational 3-year study with detailed assessment of patients with COPD, to: examine the variability of CT lung density at baseline and over the time course of this study; explore the potential relation between emphysema and patient characteristics; and investigate if certain circulating biomarkers are associated with decline in CT lung density.
Section snippets
Study design and patients
Our analysis used data collected in the ECLIPSE study, as described elsewhere.8, 15, 17 In brief, patients between 40 and 75 years of age with COPD were included if they had a history of 10 or more pack-years of smoking, an FEV1 of less than 80% of predicted value, and a ratio of FEV1 to forced vital capacity of 0·7 or less; both were measured after bronchodilator use.
The ECLIPSE study included 2161 patients with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages II–IV COPD,
Results
The baseline characteristics of the 1928 patients are shown in table 1. Mean age was 63·4 (SD 7·1) years, 1229 (64%) were men, 695 (36%) were current smokers, and the mean post-bronchodilator FEV1 was 1·35 (SD 0·52) L (48·5% [SD 15·7] of predicted). Overall 1199 (67%) patients had evidence of emphysema on CT (defined as an attenuation area >10%), 625 (32%) reported symptoms of chronic bronchitis, and 395 (22%) had both emphysema and chronic bronchitis at baseline (table 1). Patients with less
Discussion
This study confirms that the presence and severity of emphysema varies greatly in patients with COPD and identifies several clinical (older age, male gender, low BMI, former smoking, severity of airflow limitation, and previous exacerbations) and biochemical (SP-D and sRAGE) factors associated with emphysema. It also shows that the progression of emphysema over time (annual PD15 change) can be measured and varies substantially between patients (depending on sex, BMI, and smoking status), and
References (39)
- et al.
“Density mask”. An objective method to quantitate emphysema using computed tomography
Chest
(1988) - et al.
Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort
Acad Radiol
(2011) - et al.
Progression parameters for emphysema: a clinical investigation
Respir Med
(2007) - et al.
Computed tomography of the lung. Densitometric studies
Radiol Clin North Am
(1983) - et al.
Surfactant proteins SP-A and SP-D: structure, function and receptors
Mol Immunol
(2006) - et al.
Changes in forced expiratory volume in 1 second over time in COPD
N Engl J Med
(2011) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease
- et al.
Lung structure and function in cigarette smokers
Thorax
(1994) - et al.
The nature of small-airway obstruction in chronic obstructive pulmonary disease
N Engl J Med
(2004) - et al.
Small-airway obstruction and emphysema in chronic obstructive pulmonary disease
N Engl J Med
(2011)
Pulmonary emphysema: objective quantification at multi-detector row CT—comparison with macroscopic and microscopic morphometry
Radiology
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes lung volumes and emphysema in smokers with interstitial lung abnormalities
Radiology
Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Prediction of the rate of decline in FEV1 in smokers using quantitative computed tomography
Thorax
A randomized clinical trial of α1-antitrypsin augmentation therapy
Am J Respir Crit Care Med
Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency
Eur Respir J
Characterisation of COPD heterogeneity in the ECLIPSE cohort
Respir Res
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE)
Eur Respir J
Cited by (227)
Nine controversial questions about augmentation therapy for alpha-1 antitrypsin deficiency: a viewpoint
2023, European Respiratory ReviewThe Clinical Application of Established and Emerging Biomarkers for Chronic Respiratory Diseases
2023, Journal of Clinical MedicineQuantitative Computed Tomography Analysis of the Longitudinal Change between Centrilobular and Paraseptal Emphysema Subtypes: A Retrospective Study
2023, Journal of Computer Assisted TomographyAn Update on Outcomes for COPD Pharmacological Trials: A COPD Investigators Report - Reassessment of the 2008 American Thoracic Society/European Respiratory Society Statement on Outcomes for COPD Pharmacological Trials
2023, American Journal of Respiratory and Critical Care Medicine
- †
Members of the ECLIPSE steering and scientific committees and the study investigators are listed in the appendix